Our advertisers

Milton Pharmaceuticals Co UK Ltd
Baxter Healthcare Ltd
CliniMed Limited
Intersurgical Ltd
Central Medical Supplies Ltd
Nutricia Ltd
Medela AG
Armstrong Medical
Vygon (UK) Ltd
SBK (UK) Ltd
vCreate Neonatal
Solus Medical Limited
ParAid
The Brazelton Centre UK
University of Plymouth
Inspiration Healthcare

 

 

Volume 15/Issue 4, July 2019

Neonatal abstinence syndrome: a current update

Rohit Kumar, Shalabh Garg


There is an absence of consensus with regard to the monitoring and assessment of neonatal abstinence syndrome (NAS) symptoms and severity, and commencement of pharmacological treatment. As a result different treatment practices have evolved locally, nationally and internationally. The main goals of NAS therapy are to promote infant and maternal regulation and to minimise the signs of NAS expression in the infant by optimising the environment and using pharmacotherapy only when necessary. This article reviews current NAS understanding including antenatal approaches, community-based programmes, follow-up, knowledge gaps and potential future research ideas.

Kumar R., Garg S. Neonatal abstinence syndrome: a current update. Infant 2019;15(4): 132-36.
Abbreviated: Please subscribe and log in to see the full article.

 
© Copyright of Stansted News Limited 2019. Terms & Conditions of reading. Privacy policy